sign in sign up
<<
Home , CoVLP, Vaccine trial

COVID-19 Candidates Information Updated: 02/12/2021

Manufacturer Doses Handling + Efficacy Timeline of Fed Govt Technology/Type Requirements Administration Development Contract Pfizer/BioNTech mRNA vaccine Distributed at -70 ᵒC Original Mix with diluent Reported 95% EUA granted Dec. 100 mil Stable for 5 hrs: 2-8 for 5 doses/vial in on site. efficacy (Press 11, 2020. doses in 2 dose series 21 ᵒC protocol. Changed Release) original days apart to 6 doses per Once one vial began purchase. Stable for up to 30 vial. removed from Efficacy reduced Dec. 14, 2020 days in shipping box pizza box, the towards UK and Additional if dry ice is FDA advises to entire box is South African 100 mil maintained use all available considered as Variants (Press purchased doses, ideally 6 or having started Release). Dec.23, even 7. to thaw. 2020.

Minimum order: 975 doses (based on 5 doses per vial) Moderna mRNA vaccine Lasts for 6 months 10 doses/vial No dilution or Reported 94.1% EUA granted Dec. 100 mil in freezer special handling efficacy (Press 18, 2020. doses in 2 dose series 28 Minimum order is on site. Release) original days apart 30 days in fridge 10 vials: 100 doses Vaccination began purchase. Efficacy reduced Dec. 21,2020. 12 hours at room towards UK and Additional temperature South African 100 mil Variants (Press purchased 6 hours once vial is Release). on Dec. 11, pierced (Press 2020. Release) Janssen (+ 1 dose Storage at 2-8 ᵒC for 5 dose/vial of No preservative Reported 66% Filed for EUA Feb 100 million Johnson & Adenovirus up to three months 0.5mL dose in vial, no efficacy globally and 4, 2021. doses, with Johnson) Vector based reconstitution 72% within the US. option to vaccine After first use lasts They have been required at site. 85% effective in VRBPAC meeting buy up to for 6 hours at 2-8 ᵒC unable to draw up preventing severe scheduled for Feb. 200 million a 6th dose. Do not . These 26, 2021 additional vigorously lower efficacies are doses. 1

Room temperature 10 vials per shake, but attributed to the data coming carton, 48 cartons otherwise can study being done per shipper = handle driving while SARS-CoV-2 Expected to remain 2400 doses per on bumpy roads variants were stable for up to two shipper or being jostled. predominant in years at -20° C. study areas where Information Pfizer and Moderna coming on exact studies were minimum order. completed prior to variants becoming predominant in certain areas. AstraZeneca Adenovirus Storage at 2-8 ᵒC for No dilution or 90% reported for A phase III trial in 300 mil and Oxford Vector based, 2 6 months reconstitution the group who the US of 30,000 doses doses received a half dose participants is After first puncture, and then a full dose. expected to yield store up to 6 hours clarifying results at room 60% reported for on the best dose temperature or up the group who regimen. File for to 48 hours at 2-8 received 2 full doses EUA expected late ᵒC (read more here) April/May

Feb 2, 2021: reported single dose 76% efficacy and after second dose given 12 weeks later was 82.4%. Data also suggests reduced transmission in addition to prevention of symptoms (here) NOVAVAX Prefusion spike Storage at 2-8 ᵒC 10 doses/vial Co-formulated Phase III trial in US 100 mil protein with co- Handling at room with adjuvant. began Dec. 28, doses formulated with temp: 25 ᵒC Minimum order: No mixing 2020 with goal of assume 100 doses required. 2

adjuvant (2 dose Very stable under enrolling 30,000 series) stress conditions, participants (here) will utilize standard In UK 89.3% efficacy reported after Phase 3 trial with 50% of cases attributed to new variant in UK. Shown effective in Phase 2b trial in South Africa where over 90% of cases attributed to new variant (here).

Rolling Review with FDA going on now. MEDICAGO Plant produced Stable at 4-8 ᵒC 10 doses/vial 1 dose of Nov. 10 -Like product + 1 announced 100% Particle COVID- Minimum order: dose of adjuvant of participants in 19 vaccine assume 100 doses Mixed on site Phase I trials candidate developed (CoVLP) is . composed of recombinant Phase II/III trial spike (S) began Nov. 12, glycoprotein 2020. expressed as -like particles (VLPs).

2 dose series 21 days apart INOVIO INO-4800 DNA Stable at 25 ᵒC for 10 doses/vial CELLECTRA Phase 1 data vaccine (2-dose >1 year, hand-held smart published on June series) 37 ᵒC for >2 months device uses 30, 2020. 3

In buffer, 2-8 ᵒC for Minimum order: electrical pulse >5 years assume 100 doses to deliver Phase II clinical started Dec. 2020. FDA approval of Phase III trial CELLECTRA began by the end device of the second continues to quarter of 2021 delay start of PhaseII/III Sanofi Pasteur + recombinant Storage 2-8 ᵒC for 10 doses of Recombinant Began Phase I/II on 100 mil GlaxoSmithKline protein product and product/vial vaccine product Sept. 3, 2020. doses adjuvanted adjuvant 10 doses + adjuvant vaccine (2 dose adjuvant/vial Disappointing + optional series) Administration: 25 Mixed on site. phase I/II results, purchase of ᵒC Minimum order: will begin Phase 500 mil assume 100 doses 2b trial with doses modified vaccine product February 2021. Sanofi Pasteur + mRNA vaccine Storage at -20 ᵒC Minimum order: Oct 15. Announced TranslateBio MRT5500 (2-dose assume 100 doses promising series) preclinical results. Anticipate beginning phase I/II in early 2021 MERCK + IAVI DISCONTINUED (V590) MERCK #2 DISCONTINUED (V591)

Sources: • https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html • https://www.nytimes.com/2020/11/24/health/astrazeneca-covid-vaccine.html • https://www.jnj.com/johnson-johnson-initiates-second-global-phase-3-clinical-trial-of-its-janssen-covid-19-vaccine-candidate • https://www.nih.gov/news-events/news-releases/phase-3-trial-novavax-investigational-covid-19-vaccine-opens 4

• https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html • https://www.reuters.com/article/health-coronavirus-astrazeneca-vaccine/u-s-astrazeneca-vaccine-trial-will-clear-confusion-on-how-well-it-works-u-s- scientist-idUSKBN28H1YL • http://s23.q4cdn.com/479936946/files/doc_news/INOVIO-and-Advaccine-Announce-First-Dosing-of-Subject-in-Phase-2-Clinical-Trial-for-COVID-19-DNA- Vaccine-Candidate-INO-4800-in-China-2020.pdf • https://www.medicago.com/en/newsroom/medicago-and-gsk-announce-start-of-phase-2-3-clinical-trials-of-adjuvanted-covid-19-vaccine-candidate/ • https://www.sanofi.com/en/about-us/our-stories/sanofi-s-response-in-the-fight-against-covid-19 • https://www.ox.ac.uk/news/2021-02-02-oxford-coronavirus-vaccine-shows-sustained-protection-76-during-3-month-interval • https://www.biopharma-reporter.com/Article/2021/01/29/J-J-to-seek-EUA-for-single-shot-COVID-19-vaccine-in-early-February • https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-01/02-COVID-Villafana.pdf • https://www.reuters.com/article/us-health-coronavirus-inovio-pharma/inovio-expects-to-begin-late-stage-covid-19-vaccine-study-in-second-quarter- idUSKBN2991HR •

5